Lithium neuroprotection: Molecular mechanisms and clinical implications

Expert Reviews in Molecular Medicine

Volumn 6, Issue 21, 2004, Pages

  Rowe, Michael K ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Apoptosis; Excitotoxicity; GSK 3; Lithium; Neuroprotection; NMDA

Indexed keywords

AMYLOID BETA PROTEIN; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM; CARBAMAZEPINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; LAMOTRIGINE; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR AP 1; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; NERVE PROTEIN; NEUROPROTECTIVE AGENT; TRANQUILIZER;

ALZHEIMER DISEASE; APOPTOSIS; BIPOLAR DISORDER; BRAIN DAMAGE; BRAIN DISEASE; BRAIN INJURY; CALCIUM TRANSPORT; CELL SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL STUDY; DEGENERATIVE DISEASE; DOWNSTREAM PROCESSING; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; INHIBITION KINETICS; MOLECULAR MECHANICS; MOOD DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; CEREBROVASCULAR ACCIDENT; CHRONIC BRAIN DISEASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM;

ANTIMANIC AGENTS; APOPTOSIS; BIPOLAR DISORDER; BRAIN DAMAGE, CHRONIC; BRAIN INJURIES; CEREBROVASCULAR ACCIDENT; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LITHIUM; MALE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 17044371692     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399404008385     Document Type: Review

References (143)

1. Cade, J.F.J. (1949) Lithium salt's in the treatment of psychotic excitement. Medical Journal of Australia 36, 349-352
2. Schou, M. (2001) Lithium treatment at 52. J Affect Disord 67, 21-32,
3. Johnson, F.N. (1984) The History of Lithium Treatment, McMillan, London
4. Nonaka, S., Hough, C.J. and Chuang, D.M. (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 95, 2642-2647,
5. Jope, R.S. (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4, 117-128,
6. Li, X., Ketter, T.A. and Frye, M.A. (2002) Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord 69, 1-14,
7. American Psychiatric Association (1994) Diagnosis and Statistical Manual of Mental Disorders (4th edn), American Psychiatric Association, Washington, DC
8. Narrow, W.E. et al. (2002) Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 59, 115-123,
9. World Health Organization (2003) World Health Report 2003, WHO, Geneva, Switzerland
10. Kang, H.J. et al. (2003) Calcium-dependent prevention of neuronal apoptosis by lithium ion: essential role of phosphoinositide 3-kinase and phospholipase Cgamma. Mol Pharmacol 64, 228-234,
11. Lawen, A. (2003) Apoptosis-an introduction. Bioessays 25, 888-896,
12. Cory, S. and Adams, J.M. (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2, 647-656,
13. Miyashita, T. et al. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805,
14. Loeffler, M. and Kroemer, G. (2000) The mitochondrion in cell death control: certainties and incognita. Exp Cell Res 256, 19-26,
15. Earnshaw, W.C., Martins, L.M. and Kaufmann, S.H. (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68, 383-424,
16. Huang, E.J. and Reichardt, L.F. (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochern 72, 609-642,
17. Franke, T.F. et al. (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22, 8983-8998,
18. Chang, F. et al. (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 22, 469-480,
19. Doble, B.W. and Woodgett, J.R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186,
20. Bournat, J.C., Brown, A.M. and Soler, A.P (2000) Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells. J Neurosci Res 61, 21-32,
21. Bijur, G.N., De Sarno, P. and Jope, R.S. (2000) Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 275, 7583-7590,
22. Li, R., Shen, Y. and El-Mallakh, R.S. (1994) Lithium protects against ouabain-induced cell death. Lithium 5, 211-216
23. Hennion, J.P. et al. (2002) Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord 4, 201-206,
24. Nonaka, S., Katsube, N. and Chuang, D.M. (1998) Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 286, 539-547,
25. D'Mello, S.R., Anelli, R. and Calissano, P. (1994) Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons. Exp Cell Res 211, 332-338,
26. Mora, A. et al. (2001) Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J Neurochem 78, 199-206,
27. Hashimoto, R. et al. (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80, 589-597,
28. Alvarez, G. et al. (1999) Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 453, 260-264,
29. Wei, H. et al. (2000) beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur J Pharmacol 392, 117-123,
30. Tseng, W.P. and Lin-Shiau, S.Y. (2002) Long-term lithium treatment prevents neurotoxic effects of beta-bungarotoxin in primary cultured neurons. J Neurosci Res 69, 633-641,
31. Watkins, J. and Collingridge, G. (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends. Pharmacol Sci 15, 333-342,
32. Choi, D.W. (1992) Excitotoxic cell death. J Neurobiol 23, 1261-1276,
33. Nonaka, S. and Chuang, D.M. (1998) Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9, 2081-2084,
34. Xu, J. et al. (2003) Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 34, 1287-1292,
35. Senatorov, V.V. et al. (2004) Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 9, 371-385,
36. Pascual, T. and Gonzalez, J.L. (1995) A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res 695, 289-292,
37. Sparapani, M. et al. (1997) Effects of chronic lithium treatment on ornithine decarboxylase induction and excitotoxic neuropathology in the rat. Brain Res 765, 164-168,
38. Ren, M. et al. (2003) Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/ reperfusion model. Proc Natl Acad Sci U S A 100, 6210-6215,
39. Bowley, M.P. et al. (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52, 404-412,
40. Moore, G.J. et al. (2000) Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242,
41. Moore, G.J. et al. (2000) Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48, 1-8,
42. Sassi, R.B. et al. (2002) Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 329, 243-245,
43. Kieseppa, T. et al. (2003) Reduced left hemispheric white matter volume in twins with bipolar I disorder. Biol Psychiatry 54, 896-905,
44. Gould, T.D. et al. (2004) Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9, 734-755,
45. Williams, R.S. et al. (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295,
46. Martinez, R.P. and Raffa, R.B. (2002) LiCl attenuates M(1)AChR-mediated intrathecal pilocarpine-induced reciprocal hindlimb scratching in mice. Pharmacology 65, 210-214,
47. Berridge, M.J., Downes, C.P. and Hanley, M.R. (1989) Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411-419,
48. Centeno, F. et al. (1998) Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport 9, 4199-4203,
49. Huang, E.J. and Reichardt, L.F. (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24, 677-736,
50. Russo-Neustadt, A. (2003) Brain-derived neurotrophic factor, behavior, and new directions for the treatment of mental disorders. Semin Clin Neuropsychiatry 8, 109-118,
51. Klein, R. et al. (1991) The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 66, 395-403,
52. Fukumoto, T. et al. (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158, 100-106,
53. Hashimoto, R. et al. (2002) Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43, 1173-1179,
54. Brunet, A., Datta, S.R. and Greenberg, M.E. (2001) Transcription-dependent and - independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11, 297-305,
55. Chan, T.O., Rittenhouse, S.E. and Tsichlis, P.N. (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68, 965-1014,
56. Scheid, M.P. and Woodgett, J.R. (2003) Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546, 108-112,
57. Neri, L.M. et al. (2002) The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta 1584, 73-80,
58. Nicholson, K.M. and Anderson, N.G. (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14, 381-395,
59. Chalecka-Franaszek, E. and Chuang, D.M. (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96, 8745-8750,
60. Kumari, S. et al. (2001) Distinct phosphorylation patterns underlie Akt activation by different survival factors in neurons. Brain Res Mol Brain Res 96,157-162,
61. De Sarno, P., Li, X. and Jope, R.S. (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164,
62. Zhang, F. et al. (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278, 33067-33077,
63. Segal, R.A. and Greenberg, M.E. (1996) Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19, 463-489,
64. Yan, J. et al. (1998) Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273, 24052-24056,
65. Steelman, L.S. et al. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218,
66. Einat, H. et al. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23, 7311-7316,
67. Pardo, R. et al. (2003) Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 87, 417-426,
68. Tibbles, L.A. and Woodgett, J.R. (1999) The stress-activated protein kinase pathways. Cell Mol Life Sci 55, 1230-1254,
69. Mielke, K. and Herdegen, T. (2000) JNK and p38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 61, 45-60,
70. Whitmarsh, A.J. and Davis, R.J. (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74, 589-607,
71. Sionov, R.V. and Haupt, Y. (1999) The cellular response to p53: the decision between life and death. Oncogene 18, 6145-6157,
72. Chen, R.W. et al. (2003) Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem 84, 566-575,
73. Hongisto, V. et al. (2003) Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 23, 6027-6036,
74. Jope, R.S. and Bijur, G.N. (2002) Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol Psychiatry 7 Suppl 1, S35-45,
75. Grimes, C.A. and Jope, R.S. (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78, 1219-1232,
76. Jope, R.S. (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24, 441-443,
77. Stambolic, V., Ruel, L. and Woodgett, J.R. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6, 1664-1668,
78. Klein, P.S. and Melton, D.A. (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93, 8455-8459,
79. Ryves, W.J. and Harwood, A.J. (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys Res Commun 280, 720-725,
80. Wang, Q.M. et al. (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/ threonine phosphorylation. J Biol Chem 269, 14566-14574,
81. Li, X., Bijur, G.N. and Jope, R.S. (2002) Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4, 137-144,
82. Eastman, Q. and Grosschedl, R. (1999) Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 11, 233-240,
83. Roose, J. and Clevers, H. (1999) TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1424, M23-37,
84. Seidensticker, M.J. and Behrens, J. (2000) Biochemical interactions in the wnt pathway. Biochim Bióphys Acta 1495, 168-182,
85. Huelsken, J. and Behrens, J. (2002) The Wnt signalling pathway. J Cell Sci 115, 3977-3978,
86. Moon, R.T. et al. (2002) The promise and perils of Wnt signaling through beta-catenin. Science 296, 1644-1646,
87. Chen, G. et al. (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72, 1327-1330,
88. Gould, T.D., Chen, G. and Manji, H.K. (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32-38,
89. Takayama, S., Reed, J.C. and Homma, S. (2003) Heat-shock proteins as regulators of apoptosis. Oncogene 22, 9041-9047,
90. Gao, T. and Newton, A.C. (2002) The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem 277, 31585-31592,
91. Beere, H.M. et al. (2000) Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2, 469-475,
92. Mosser, D.D. et al. (2000) The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 20, 7146-7159,
93. Chu, B. et al. (1996) Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J Biol Chem 271, 30847-30857,
94. Bijur, G.N. and Jope, R.S. (2000) Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem 75, 2401-2408,
95. Xavier, I.J. et al. (2000) Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem 275, 29147-29152,
96. Shaulian, E. and Karin, M. (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-136,
97. Boyle, W.J. et al. (1991) Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64, 573-584,
98. Karin, M. (1998) Mitogen-activated protein kinase cascades as regulators of stress responses. Ann N Y Acad Sci 851, 139-146,
99. Wisdom, R. (1999) AP-1: one switch for many signals. Exp Cell Res 253, 180-185,
100. Ozaki, N. and Chuang, D.M. (1997) Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 69, 2336-2344,
101. Asghari, V. et al. (1998) Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 58, 95-102,
102. Impey, S. et al. (1996) Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16, 973-982,
103. Bonni, A. et al. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358-1362,
104. Kopnisky, K.L. et al. (2003) Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 116, 425-435,
105. Hansen, T.O., Rehfeld, J.F. and Nielsen, F.C. (2004) GSK-3beta reduces cAMP-induced cholecystokinin gene expression by inhibiting CREB binding. Neuroreport 15, 841-845,
106. Finkbeiner, S. (2000) CREB couples neurotrophin signals to survival messages. Neuron 25, 11-14,
107. Freeland, K., Boxer, L.M. and Latchman, D.S. (2001) The cyclic AMP response element in the Bcl-2 promoter confers inducibility by hypoxia in neuronal cells. Brain Res Mol Brain Res 92, 98-106,
108. Shieh, P.B. et al. (1998) Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20, 727-740,
109. Chen, R.W. and Chuang, D.M. (1999) Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274, 6039-6042,
110. Manji, H.K., Moore, G.J. and Chen, G. (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61 Suppl 9, 82-96,
111. Corson, T.W. et al. (2004) Cell-type specific regulation of calreticulin and Bcl-2 expression by mood stabilizer drugs. Eur Neuropsychopharmacol 14, 143-150,
112. Stout, A.K. et al. (1998) Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci 1, 366-373,
113. Sattler, R. and Tymianski, M. (2001) Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol 24, 107-129,
114. Yu, X.M. et al. (1997) NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 275, 674-678,
115. Salter, M.W. (1998) Src, N-methyl-D-aspartate (NMDA) receptors, and synaptic plasticity. Biochem Pharmacol 56, 789-798,
116. Ali, D.W. and Salter, M.W. (2001) NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr Opin Neurobiol 11, 336-342,
117. Takasu, M.A. et al. (2002) Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science 295, 491-495,
118. Lavezzari, G. et al. (2003) Differential binding of the AP-2 adaptor complex and PSD-95 to the C-terminus of the NMDA receptor subunit NR2B regulates surface expression. Neuropharmacology 45, 729-737,
119. Hashimoto, R. et al. (2003) Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Lett 538, 145-148,
120. Takagi, N. et al. (1997) Transient ischemia differentially increases tyrosine phosphorylation of NMDA receptor subunits 2A and 2B. J Neurochem 69, 1060-1065,
121. Liu, Y. et al. (2001) NMDA receptor activation results in tyrosine phosphorylation of NMDA receptor subunit 2A(NR2A) and interaction of Pyk2 and Src with NR2A after transient cerebral ischemia and reperfusion. Brain Res 909, 51-58,
122. Hou, X.Y. et al. (2002) Activation of NMDA receptors and L-type voltage-gated calcium channels mediates enhanced formation of Fyn-PSD95-NR2A complex after transient brain ischemia. Brain Res 955, 123-132,
123. Ma, J. and Zhang, G.Y. (2003) Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neurosci Lett 348, 185-189,
124. Manji, H.K. and Duman, R.S. (2001) Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 35, 5-49,
125. Ketter, T.A., Manji, H.K. and Post, R.M. (2003) Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 23, 484-495,
126. Drevets, W.C. (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11, 240-249,
127. Manji, H.K. et al. (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53, 707-742,
128. Post, R.M. et al. (2003) Neurobiology of bipolar illness: implications for future study and therapeutics. Ann Clin Psychiatry 15, 85-94,
129. Friedlander, R.M. (2003) Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348, 1365-1375,
130. Janardhan, V. and Qureshi, A.I. (2004) Mechanisms of ischemic brain injury. Curr Cardiol Rep 6, 117-123,
131. Wahlgren, N.G. and Ahmed, N. (2004) Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc Dis 17 Suppl 1, 153-166,
132. Lipton, P. (1999) Ischemic cell death in brain neurons. Physiol Rev 79, 1431-1568,
133. Chuang, D.M. et al. (2002) Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 4, 129-136,
134. Selkoe, D.J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766,
135. Hong, M. et al. (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272, 25326-25332,
136. Alvarez, G. et al. (2002) Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4, 153-165,
137. Phiel, C.J. et al. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439,
138. Hickey, M.A. and Chesselet, M.F. (2003) Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 27, 255-265,
139. Wei, H. et al. (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106, 603-612,
140. Carmichael, J. et al. (2002) Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 277, 33791-33798,
141. Zuccato, C. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498,
142. Humbert, S. et al. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease an involves Huntingtin phosphorylation by Akt. Dev Cell 2, 831-837,
143. Chuang, D.M. Lithium protection from excitotoxicity: therapeutic implications. Clin Neurosci Res (in press)